2024-515021-29-00CompletedPhase 1
A Randomized, Placebo-Controlled, Double-Blind, Single Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living With ALS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 8 Jul 2024
- Start date
- 11 Nov 2024
- Lead sponsor
- Quralis Corp.
- Diseases
- ALS (motor neurone disease)
- EU CT number
- 2024-515021-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Completed |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.